Tata Elxsi Expects Improved H2 Performance Driven By Healthcare Vertical

Market snapshot: Tata Elxsi management expects improved performance in the second half of FY27 compared to H1, driven by a strong deal pipeline in Healthcare & Life Sciences. While the European automotive market presents near-term headwinds, expansion in medical engineering and aerospace provides structural support.

Data Snapshot

• Tata Elxsi reported Q2 FY27 operating revenue of ₹1,055.7 crore, up 3.4% QoQ and 15% YoY.
• EBITDA reached ₹231.4 crore with an EBITDA margin of 21.9%, registering a 7.1% QoQ growth.
• Healthcare & Life Sciences vertical registered constant currency revenue growth of 3.5% QoQ in Q2 FY27.

What's Changed

• Healthcare & Life Sciences vertical accelerated to 3.5% QoQ growth in constant currency terms.
• Q2 FY27 operating revenue reached ₹1,055.7 crore, up 3.4% QoQ and 15% YoY.
• EBITDA margin expanded to 21.9% with absolute EBITDA of ₹231.4 crore.

Key Takeaways

• Healthcare & Life Sciences deal pipeline is expected to drive higher operational performance in H2.
• Management guidance indicates H2 FY27 performance will surpass H1 FY27.
• European automotive sector caution continues to restrict near-term growth in transportation ER&D.

SAHI Perspective

Tata Elxsi's strategic focus on AI-driven healthcare product engineering and digital therapeutics is delivering strong diversification benefits. By offsetting cautious OEM spending in Europe with growth in healthcare and media verticals, the company maintains margin stability while positioning for a stronger H2.

Market Implications

Revenue diversification away from purely automotive ER&D reduces earnings volatility. Stable margins at 21.9% and steady pipeline conversions in healthcare support mid-term operational metrics.

Trading Signals

Market Bias: Bullish

Supported by Q2 FY27 operating revenue of ₹1,055.7 crore (+3.4% QoQ) and stable EBITDA margins of 21.9%, positive guidance for H2 healthcare growth underpins market sentiment.

Overweight: Healthcare & Life Sciences ER&D, Media & Communications

Underweight: European Automotive ER&D

Trigger Factors:

• Deal conversion momentum in Healthcare & Life Sciences in H2
• Recovery in European OEM R&D spend
• EBITDA margin defense above 21.5%

Time Horizon: Medium-term (3-12 months)

Industry Context

Global engineering research and development service providers are witnessing divergence across sectors, with automotive client budgets constrained in Europe while medtech, digital health, and aerospace demand remain resilient.

Key Risks to Watch

• Prolonged sluggishness in European automotive client budgets.
• Delays in pipeline deal conversions in the Healthcare vertical.
• Foreign exchange fluctuations affecting overseas revenue.

Recent Developments

In October 2026, Tata Elxsi reported Q2 FY27 operating revenue of ₹1,055.7 crore (+3.4% QoQ, +15% YoY) with an EBITDA margin of 21.9%.

Closing Insight

Vertical diversification into medical devices and digital health engineering provides Tata Elxsi with structural protection against regional automotive slowness through H2 FY27.

High Performance Trading with SAHI.